1. Van der Knaap MS, Valk J. Magnetic
resonance of myelination and myelin disorders. 3rd ed.
Berlin: Springer; 2005.
2. Peters C, Steward CG. Hematopoietic cell transplantation
for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone
Marrow Transplant. Feb 2003;31(4):229-239.
3. Bezman L, Moser AB, Raymond GV, et al. Adrenoleukodystrophy:
incidence, new mutation rate, and results of extended family screening. Ann
Neurol. 2001;49(4):512-517.
4. Moser HW, Moser AB, Steinberg SJ, Raymond GV. X-linked adrenoleukodystrophy.
www.geneclinics.org.
Accessed May 20, 2008.
5. Kemp S, Wanders RJ. X-linked adrenoleukodystrophy: very long-chain
fatty acid metabolism, ABC half-transporters and the complicated
route to treatment. Mol Genet Metab. 2007;90(3):268-276.
6. Moser HW, Moser AB, Hollandsworth K, Brereton NH, Raymond
GV. “Lorenzo’s oil” therapy for X-linked
adrenoleukodystrophy: rationale and current assessment of efficacy. J
Mol Neurosci. 2007;33(1):105-113.
7. Hudspeth MP, Raymond GV. Immunopathogenesis of adrenoleukodystrophy:
current understanding. J Neuroimmunol. 2007;182(1-2):5-12.
8. Moser HW, Naidu S, Kumar AJ, Rosenbaum AE. The adrenoleukodystrophies. Crit
Rev Neurobiol. 1987;3(1):29-88.
9. Loes DJ, Fatemi A, Melhem ER, et al. Analysis of MRI patterns
aids prediction of progression in X-linked adrenoleukodystrophy.
Neurology. 2003;
61(3):369-374.
[PubMed: 12913200]
10. Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy:
the international hematopoietic cell transplantation experience
from 1982 to 1999. Blood. 2004;104(3):881-888.
11. Mahmood A, Raymond GV, Dubey P, Peters C, Moser HW. Survival
analysis of haematopoietic cell transplantation for childhood cerebral
X-linked adrenoleukodystrophy: a comparison study. Lancet
Neurol. 2007;6(8):687-692.
12. Cox CS, Dubey P, Raymond GV, Mahmood A, Moser AB, Moser
HW. Cognitive evaluation of neurologically asymptomatic boys with
X-linked adrenoleukodystrophy. Arch Neurol. 2006;63(1):69-73.
13. Rice G, Patrick T, Parmar R, et al. Clinical and molecular
phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet. 2007;81(4):713-725.
15. Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D,
Goldman JE, Messing A. Mutations in GFAP, encoding glial fibrillary
acidic protein, are associated with Alexander disease. Nat
Genet. 2001;27(1):117-120.
16. Li R, Johnson AB, Salomons G, et al. Glial fibrillary acidic
protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann
Neurol. 2005;57(3):310-326.
17. Gorospe JR, Maletkovic J. Alexander disease and megalencephalic
leukoencephalopathy with subcortical cysts: leukodystrophies arising
from astrocyte dysfunction. Ment Retard Dev Disabil Res
Rev. 2006;12(2):113-122.
18. van der Knaap MS, Naidu S, Breiter SN, et al. Alexander
disease: diagnosis with MR imaging. AJNR Am J Neuroradiol. 2001;22(3):541-552.
19. van der Knaap MS, Ramesh V, Schiffmann R, et al. Alexander disease:
ventricular garlands and abnormalities of the medulla and spinal
cord. Neurology. 2006;66(4):494-498.
21. Madhavarao CN, Arun P, Moffett JR, et al. Defective N-acetylaspartate
catabolism reduces brain acetate levels and myelin lipid synthesis
in Canavan’s disease. Proc Natl Acad Sci USA. 2005;102(14):5221-5226.
22. Baslow MH. Brain N-acetylaspartate as a molecular water
pump and its role in the etiology of Canavan disease: a mechanistic
explanation. J Mol Neurosci. 2003;21(3):185-190.
23. Traeger EC, Rapin I. The clinical course of Canavan disease. Pediatr
Neurol. 1998;18(3):207-212.
24. Leone P, Janson CG, Bilaniuk L, et al. Aspartoacylase gene
transfer to the mammalian central nervous system with therapeutic
implications for Canavan disease. Ann Neurol. Jul
2000;48(1):27-38.
25. Janson CG, Assadi M, Francis J, Bilaniuk L, Shera D, Leone
P. Lithium citrate for Canavan disease. Pediatr Neurol. 2005;33(4):235-243.
26. Golomb MR, Sokol DK, Walsh LE, Christensen CK, Garg BP.
Recurrent hemiplegia, normal MRI, and NOTCH3 mutation in a 14-year-old:
is this early CADASIL? Neurology. 22 2004;62(12):2331-2332.
27. Dichgans M, Mayer M, Uttner I, et al. The phenotypic spectrum of
CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44(5):731-739.
29. Barone R, Bruhl K, Stoeter P, Fiumara A, Pavone L, Beck
M. Clinical and neuroradiological findings in classic infantile
and late-onset globoid-cell leukodystrophy (Krabbe disease). Am
J Med Genet. 1996;63(1):209-217.
30. Siddiqi ZA, Sanders DB, Massey JM. Peripheral neuropathy
in Krabbe disease: electrodiagnostic findings. Neurology. 2006;67(2):263-267.
31. Husain AM, Altuwaijri M, Aldosari M. Krabbe disease: neurophysiologic
studies and MRI correlations. Neurology. 2004;63(4):617-620.
32. Krivit W, Shapiro EG, Peters C, et al. Hematopoietic stem-cell
transplantation in globoid-cell leukodystrophy. N Engl J
Med. 1998;338(16):1119-1126.
33. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation
of umbilical-cord blood in babies with infantile Krabbe’s
disease. N Engl J Med. 2005;352(20):2069-2081.
34. Escolar ML, Poe MD, Martin HR, Kurtzberg J. A staging system
for infantile Krabbe disease to predict outcome after unrelated
umbilical cord blood transplantation. Pediatrics. 2006;118(3):e879-e889.
35. Siddiqi ZA, Sanders DB, Massey JM. Peripheral neuropathy
in Krabbe disease: effect of hematopoietic stem cell transplantation. Neurology. 2006;67(2):268-272.
36. van der Knaap MS, Linnankivi T, Paetau A, et al. Hypomyelination
with atrophy of the basal ganglia and cerebellum: follow-up and
pathology. Neurology. 2007;69(2):166-171.
37. Fluharty A. Arylsulfatase A deficiency. May 30, 2006;
www.geneclinics.org.
Accessed May 29, 2008.
38. Gieselmann V. Metachromatic leukodystrophy: genetics, pathogenesis
and therapeutic options. Acta Paediatr Suppl. 2008;97(457):15-21.
39. Rauschka H, Colsch B, Baumann N, et al. Late-onset metachromatic
leukodystrophy: genotype strongly influences phenotype. Neurology. 2006;67(5):859-863.
40. Sevin C, Aubourg P, Cartier N. Enzyme, cell and gene-based
therapies for metachromatic leukodystrophy. J Inherit Metab
Dis. 2007;30(2):175-183.
41. Cameron CL, Kang PB, Burns TM, Darras BT, Jones HR Jr. Multifocal
slowing of nerve conduction in metachromatic leukodystrophy. Muscle
Nerve. 2004;29(4):531-536.
42. Krivit W. Allogeneic stem cell transplantation for the treatment
of lysosomal and peroxisomal metabolic diseases. Springer
Semin Immunopathol. 2004;26(1-2):119-132.
43. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W.
Allogeneic mesenchymal stem cell infusion for treatment of metachromatic
leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone
Marrow Transplant. 2002;30(4):215-222.
44. Bredius RG, Laan LA, Lankester AC, et al. Early marrow transplantation
in a pre-symptomatic neonate with late infantile metachromatic leukodystrophy does
not halt disease progression. Bone Marrow Transplant. 2007;39(5):309-310.
45. Garbern JY, Krajewski K, Hobson G. PLP1-related disorders.
2006;
www.geneclinics.org. Accessed May 29, 2008.
46. Gow A, Southwood CM, Lazzarini RA. Disrupted proteolipid protein
trafficking results in oligodendrocyte apoptosis in an animal model
of Pelizaeus-Merzbacher disease. J Cell Biol. 1998;140(4):925-934.
47. Inoue K. PLP1-related inherited dysmyelinating disorders:
Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics. 2005;6(1):1-16.
48. Cailloux F, Gauthier-Barichard F, Mimault C, et al. Genotype-phenotype
correlation in inherited brain myelination defects due to proteolipid
protein gene mutations. Clinical European Network on Brain Dysmyelinating Disease. Eur
J Hum Genet. 2000;8(11):837-845.
49. Henneke M, Combes P, Diekmann S, et al. GJA12 mutations
are a rare cause of Pelizaeus-Merzbacher-like disease. Neurology. 2008;70(10):748-754.
50. van der Knaap MS, Pronk JC, Scheper GC. Vanishing white matter
disease. Lancet Neurol. 2006;5(5):413-423.
51. Linnankivi T, Tienari P, Somer M, et al. 18q deletions:
clinical, molecular, and brain MRI findings of 14 individuals. Am
J Med Genet A. 2006;140(4):331-339.